| Literature DB >> 27812542 |
Masashi Masuda1, Shinobu Miyazaki-Anzai1, Audrey L Keenan1, Yuji Shiozaki1, Kayo Okamura1, Wallace S Chick2, Kristina Williams2, Xiaoyun Zhao2, Shaikh Mizanoor Rahman3, Yin Tintut4, Christopher M Adams5, Makoto Miyazaki1.
Abstract
Emerging evidence indicates that upregulation of the ER stress-induced pro-osteogenic transcription factor ATF4 plays an important role in vascular calcification, a common complication in patients with aging, diabetes, and chronic kidney disease (CKD). In this study, we demonstrated the pathophysiological role of ATF4 in vascular calcification using global Atf4 KO, smooth muscle cell-specific (SMC-specific) Atf4 KO, and transgenic (TG) mouse models. Reduced expression of ATF4 in global ATF4-haplodeficient and SMC-specific Atf4 KO mice reduced medial and atherosclerotic calcification under normal kidney and CKD conditions. In contrast, increased expression of ATF4 in SMC-specific Atf4 TG mice caused severe medial and atherosclerotic calcification. We further demonstrated that ATF4 transcriptionally upregulates the expression of type III sodium-dependent phosphate cotransporters (PiT1 and PiT2) by interacting with C/EBPβ. These results demonstrate that the ER stress effector ATF4 plays a critical role in the pathogenesis of vascular calcification through increased phosphate uptake in vascular SMCs.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27812542 PMCID: PMC5085604 DOI: 10.1172/jci.insight.88646
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708